Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of RSV/hMPV combination and hMPV vaccines in adults
2025-524456-58-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 2 trial of IVX-A12 in respiratory syncytial virus disease (RSV) and human metapneumovirus infection (HMPV) (2 arms), sponsored by GSK. Planned start Jun 2026; status: authorised.
02
Drugs
IVX-A12
03
Conditions
respiratory syncytial virus disease (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on 2025-524456-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524456-58-00.